Table 3

Patient characteristics

CRF #

Age (years)

Time since first diagnosis of SLE

Time since first diagnosis of nephritis

LN-WHO type

Pre-treatment of LN within six months before study start


9

20

1.5 years

1.5 years

IV

Prednisone, AZA, MMF, HCQ

10

34

2.5 years

2.5 years

IV

CYC, AZA, Prednisone

11

46

11 years

11 years

IV

Prednisone, MMF

13

39

8. 5 years

4 years

V

Prednisone, MMF

14

20

2 years

4 years

IV

MMF

15

37

7 years

7 years

IV

CYC, Prednisone, CSA, AZA

16

30

17 years

17 years

IV

Prednisone,

17

40

21.5 years

21.5 years

III

AZA, Prednisone, MMF, Immunadsorption

19

20

4.5 years

4.5 years

IV

AZA, MMF, Prednisone, Methylprednisolon, HCQ, Rituximab, Octagam

26

35

9 years

8 years

IV

Prednisone, MMF

31

22, 5

3 years

3 years

IV

CYC, Prednisone

32

42

12 years

12 years

V

AZA, Methylprednisolon

33

31

7 years

7 years

IV

MMF, Prednisone, HCQ

34

19

1 year

1 year

IV

AZA, CYC, Prednison

35

42

10.5 years

10.5 years

IV

Prednisone, AZA

36

30

13 years

4 years

IV

Methylprednisolon AZA

38

22

2.5 years

2.5 years

IV

CYC, Prednisone, HCQ

39

46

2 years

2 years

IV

HCQ, plasmapheresis Prednisolone

42

29

10 years

1 year

V

Prednisone, CSA

49

37, 5

4 years

4 years

V

Prednisone, CSA

50

20

1 year

1 year

IV

Prednisone, AZA, MMF, CYC, Prednisone


AZA, azathioprin; CRF, case report form; CSA, cyclosporine A; CYC, cyclophosphamide; HCQ, hydroxychloroquine; LN, lupus nephritis; MMF, mycophenolic acid; SLE, systemic lupus erythematosus.

Lorenz et al. Arthritis Research & Therapy 2011 13:R36   doi:10.1186/ar3268

Open Data